Overall, given the demonstrated safety of CX-4945 in initial human studies, these preclinical data may justify the implementation of clinical trials using CX-4945 in combination with ATM inhibitors in a subset of HIF-2α-expressing VHL-defective ccRCC patients. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.